Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
1999-07-09
2002-04-02
Shah, Mukund J. (Department: 1609)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S253030, C514S254080, C514S290000, C544S058200, C544S361000, C546S093000
Reexamination Certificate
active
06365588
ABSTRACT:
BACKGROUND
International Publication Number WO92/11034, published Jul. 9, 1992, discloses a method of increasing the sensitivity of a tumor to an antineoplastic agent, which tumor is resistant to the antineoplastic agent, by the concurrent administration of the antineoplastic agent and a potentiating agent of the formula:
wherein the dotted line represents an optional double bond, X′ is hydrogen or halo, and Y′ is hydrogen, substituted carboxylate or substituted sulfonyl. For example, Y′ can be, amongst others, —COOR′ wherein R′ is C1 to C6 alkyl or substituted alkyl, phenyl, substituted phenyl, C7 to C12 aralkyl or substituted aralkyl or -2, -3, or -4 piperidyl or N-substituted piperidyl. Y′ can also be, amongst others, SO
2
R′ wherein R′ is C1 to C6 alkyl, phenyl, substituted phenyl, C7 to C12 aralkyl or substituted aralkyl. Examples of such potentiating agents include 11-(4-piperidylidene)-5H-benzo[5,6]cyclohepta[1,2-b]pyridines such as Loratadine.
Oncogenes frequently encode protein components of signal transduction pathways which lead to stimulation of cell growth and mitogenesis. Oncogene expression in cultured cells leads to cellular transformation, characterized by the ability of cells to grow in soft agar and the growth of cells as dense foci lacking the contact inhibition exhibited by non-transformed cells. Mutation and/or overexpression of certain oncogenes is frequently associated with human cancer.
To acquire transforming potential, the precursor of the Ras oncoprotein must undergo farnesylation of the cysteine residue located in a carboxyl-terminal tetrapeptide. Inhibitors of the enzyme that catalyzes this modification, farnesyl protein transferase, have therefore been suggested as anticancer agents for tumors in which Ras contributes to transformation. Mutated, oncogenic forms of ras are frequently found in many human cancers, most notably in more than 50% of colon and pancreatic carcinomas (Kohl et al., Science, Vol. 260, 1834 to 1837, 1993).
In view of the current interest in inhibitors of famesyl protein transferase, a welcome contribution to the art would be compounds useful for the inhibition of farnesyl protein transferase. Such a contribution is provided by this invention.
SUMMARY OF THE INVENTION
Inhibition of farnesyl protein transferase by tricyclic compounds of this invention has not been reported previously. Thus, this invention provides a method for inhibiting farnesyl protein transferase using tricyclic compounds of this invention which: (i) potently inhibit farnesyl protein transferase, but not geranylgeranyl protein transferase I, in vitro; (ii) block the phenotypic change induced by a form of transforming Ras which is a famesyl acceptor but not by a form of transforming Ras engineered to be a geranylgeranyl acceptor; (iii) block intracellular processing of Ras which is a farnesyl acceptor but not of Ras engineered to be a geranylgeranyl acceptor; and (iv) block abnormal cell growth in culture induced by transforming Ras. Several compounds of this invention have been demonstrated to have anti-tumor activity in animal models.
This invention provides a method for inhibiting the abnormal growth of cells, including transformed cells, by administering an effective amount of a compound of this invention. Abnormal growth of cells refers to cell growth independent of normal regulatory mechanisms (e.g., loss of contact inhibition). This includes the abnormal growth of: (1) tumor cells (tumors) expressing an activated Ras oncogene; (2) tumor cells in which the Ras protein is activated as a result of oncogenic mutation in another gene; and (3) benign and malignant cells of other proliferative diseases in which aberrant Ras activation occurs.
Compounds useful in the claimed methods are represented by Formula 1.0:
or a pharmaceutically acceptable salt or solvate thereof, wherein:
one of a, b, c and d represents N or NR
9
wherein R
9
is O
−
, —CH
3
or —(CH
2
)
n
CO
2
H wherein n is 1 to 3, and the remaining a, b, c and d groups represent CR
1
or CR
2
; or
each of a, b, c, and d are independently selected from CR
1
or CR
2
;
each R
1
and each R
2
is independently selected from H, halo, —CF
3
, —OR
10
(e.g., —OCH
3
), —COR
10
, —SR
10
(e.g., —SCH
3
and —SCH
2
C
6
H
5
), —S(O)
t
R
11
(wherein t is 0, 1 or 2, e.g., —SOCH
3
and —SO
2
CH
3
), —SCN, —N(R
10
)
2
, —NR
10
R
11
, —NO
2
, —OC(O)R
10
, —CO
2
R
10
, —OCO
2
R
11
, —CN, —NHC(O)R
10
, —NHSO
2
R
10
, —CONHR
10
, —CONHCH
2
CH
2
OH, —NR
10
COOR
11
,
—SR
11
C(O)OR
11
(e.g., —SCH
2
CO
2
CH
3
), —SR
11
N(R
75
)
2
wherein each R
75
is independently selected from H and —C(O)OR
11
(e.g., —S(CH
2
)
2
NHC(O)O-t-butyl and —S(CH
2
)
2
NH
2
), benzotriazol-1-yloxy, tetrazol-5-ylthio, or substituted tetrazol-5-ylthio (e.g., alkyl substituted tetrazol-5-ylthio such as 1-methyl-tetrazol-5-ylthio), alkynyl, alkenyl or alkyl, said alkyl or alkenyl group optionally being substituted with halo, —OR
10
or —CO
2
R
10
;
R
3
and R
4
are the same or different and each independently represents H, any of the substituents of R
1
and R
2
, or R
3
and R
4
taken together represent a saturated or unsaturated C
5
-C
7
fused ring to the benzene ring (Ring III);
R
5
, R
6
, R
7
and R
8
each independently represents H, —CF
3
, —COR
10
, alkyl or aryl, said alkyl or aryl optionally being substituted with —OR
10
, —SR
10
, —S(O)
t
R
11
, —NR
10
COOR
11
, —N(R
10
)
2
, —NO
2
, —COR
10
, —OCOR
10
, —OCO
2
R
11
, —CO
2
R
10
, OPO
3
R
10
or one of R
5
, R
6
, R
7
and R
8
can be take in combination with R
40
as defined below to represent —(CH
2
)
r
— wherein r is 1 to 4 which can be substituted with lower alkyl, lower alkoxy, —CF
3
or aryl, or R
5
is combined with R
6
to represent ═O or ═S and/or R
7
is combined with R
8
to represent ═O or ═S;
R
10
represents H, alkyl, aryl, or aralkyl (e.g., benzyl);
R
11
represents alkyl or aryl;
X represents N, CH or C, which C may contain an optional double bond (represented by the dotted line) to carbon atom 11;
the dotted line between carbon atoms 5 and 6 represents an optional double bond, such that when a double bond is present, A and B independently represent —R
10
, halo, —OR
11
, —OCO
2
R
11
or —OC(O)R
10
, and when no double bond is present between carbon atoms 5 and 6, A and B each independently represent H
2
, —(OR
11
)
2
; H and halo, dihalo, alkyl and H, (alkyl)
2
, —H and —OC(O)R
10
, H and —OR
10
, ═O, aryl and H, ═NOR
10
or —O—(CH
2
)
p
—O— wherein p is 2, 3 or 4;
R represents R
40
, R
42
, R
44
, or R
54
, as defined below;
R
40
represents H, aryl, alkyl, cycloalkyl, alkenyl, alkynyl or —D wherein —D represents
wherein R
3
and R
4
are as previously defined and W is O, S or NR
10
wherein R
10
is as defined above; said R
40
cycloalkyl, alkenyl and alkynyl groups being optionally substituted with from 1-3 groups selected from halo, —CON(R
10
)
2
, aryl, —CO
2
R
10
, —OR
12
, —SR
12
, —N(R
10
)
2
, —N(R
10
)CO
2
R
11
, —COR
12
, —NO
2
or D, wherein —D, R
10
and R
11
are as defined above and R
12
represents R
10
, —(CH
2
)
m
OR
10
or —(CH
2
)
q
CO
2
R
10
wherein R
10
is as previously defined, m is 1 to 4 and q is 0 to 4; said alkenyl and alkynyl R
40
groups not containing —OH, —SH or —N(R
10
)
2
on a carbon containing a double or triple bond respectively; or
R
40
represents phenyl substituted with a group selected from —SO
2
NH
2
, —NHSO
2
CH
3
, —SO
2
NHCH
3
, —SO
2
CH
3
, —SOCH
3
, —SCH
3
, or —NHSO
2
CF
3
, preferably, said group is located in the para (p-) position of the phenyl ring; or
R
40
represents a group selected from
wherein R
20
, R
21
and R
46
are each independently selected from the group consisting of:
(1) H;
(2) —(CH
2
)
q
SC(O)CH
3
wherein q is 1 to 3 (e.g., —CH
2
SC(O)CH
3
);
(3) —(CH
2
)
q
OSO
2
CH
3
wherein q is 1 to 3 (e.g., —CH
2
OSO
2
CH
3
);
(4) —OH;
(5) —CS(CH
2
)
w
(substituted phenyl) wherein w is 1 to 3 and the substitutents on said substituted phenyl group are the same substitutents as descr
Bishop Robert W.
Doll Ronald J.
Mallams Alan K.
Njoroge F. George
Petrin Joanne M.
Jeanette Henry C.
Schering Corporation
Shah Mukund J.
Truong Tamthom N.
LandOfFree
Tricyclic amide and urea compounds useful for inhibition of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tricyclic amide and urea compounds useful for inhibition of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tricyclic amide and urea compounds useful for inhibition of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2850989